Status:
COMPLETED
Behavioural Weight Loss Treatment for Patients with Atrial Fibrillation and Obesity in Cardiac Rehabilitation
Lead Sponsor:
University of Calgary
Conditions:
Atrial Fibrillation
Obesity
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
One-in-four Canadians will be diagnosed with an abnormal heart rhythm called atrial fibrillation (AF) in their lifetime. People with AF have an increased chance of having serious medical problems like...
Detailed Description
Background: One-in-four Canadians will develop atrial fibrillation (AF), increasing risk of heart failure and stroke. Obesity (i.e., BMI ≥30 kg/m2) represents a strong, independent risk factor for inc...
Eligibility Criteria
Inclusion
- 18+ years
- symptomatic, electrocardiogram (ECG)-documented paroxysmal (i.e., ≥2 AF episodes within a 6 month period) or persistent (i.e., AF episodes lasting ≥7 days) AF
- obesity (i.e., BMI ≥30 kg/m2)
- able to read and write in English to be eligible.
Exclusion
- longstanding-persistent (i.e., ≥ 3 years continuous AF) or permanent AF;
- uncontrolled CAD;
- currently enrolled in a concurrent weight loss program, and;
- currently scheduled to receive catheter ablation treatment for AF.
Key Trial Info
Start Date :
January 24 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2023
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT05230823
Start Date
January 24 2022
End Date
January 31 2023
Last Update
December 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Calgary
Calgary, Alberta, Canada, T2N1N4